-
-
-
-
-
-
-
Agile Therapeutics (AGRX) Announces FDA Extension of Twirla NDA Review Period
-
-
-
-
-
-
-
Agile Therapeutics (AGRX) Provides Twirla Update, Other Recent Corporate Developments
-
-
-
-
-
-
-
Agile Therapeutics Announces FDA Advisory Committee Meeting for its Investigational Transdermal Low-Dose Contraceptive Patch, Twirla® (AG200-15)
-
-
-
-
-
-
-
Janney Assumes Agile Therapeutics (AGRX) at Buy
-
-
-
-
-
-
-
Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla® (AG200-15) for the Prevention of Pregnancy
-
-
-
-
-
-
-
Pre-Open Stock Movers 07/28: (KOOL) (SAM) (FSLR) Higher; (DEST) (ELLI) (NUVA) Lower (more...)
-
-
-
-
-
-
-
Agile Therapeutics (AGRX) Resubmits NDA for Transdermal Contraceptive Patch
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

